Literature DB >> 7867674

CYP2D6 genotype determination in the Danish population.

K Brøsen1, P N Nielsen, K Brusgaard, L F Gram, K Skjødt.   

Abstract

CYP2D6 genotyping was carried out by XbaI restriction fragment length polymorphism analysis and polymerase chain reaction in 168 healthy Danish volunteers, 77 extensive metabolizers (EM) and 91 poor metabolizers (PM) of sparteine. All EM were genotyped correctly as heterozygous or homozygous for the functional (wild type) gene, D6-wt. However, the D6-wt gene was apparently also present in 11 (12%) of the PM who accordingly were incorrectly genotyped as EM. The specificity of genotyping PM thus was 100% but the sensitivity was only 88%. The most common allele was the D6-wt with an apparent frequency of 0.741 (0.026) in the Danish population and the second most common allele was the D6-B with an apparent frequency of 0.194 (0.024). The median (range) of the sparteine metabolic ratio (MR) in 47 homozygous D6-wt EM was 0.28 (0.11-4.10) and the corresponding value in heterozygous EM was 0.36 (0.11-9.10). The median difference was 0.09 (95% confidence interval: 0.02-0.16). CYP2D6 phenotyping is a promising tool in tailoring the individual dose of tricyclic antidepressants, some neuroleplics and some antiarrhythmics. However if the genotype test could be improved with regard to both sensitivity in PM and the ability to predict CYP2D6 activity in EM then it would be of even greater clinical value in therapeutic drug monitoring.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7867674     DOI: 10.1007/bf02570501

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  36 in total

1.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

Authors:  M Heim; U A Meyer
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

2.  Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine.

Authors:  S H Sindrup; K Brøsen; P Bjerring; L Arendt-Nielsen; U Larsen; H R Angelo; L F Gram
Journal:  Clin Pharmacol Ther       Date:  1990-12       Impact factor: 6.875

3.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.

Authors:  G Alván; P Bechtel; L Iselius; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.

Authors:  E Steiner; L Iselius; G Alván; J Lindsten; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

5.  Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.

Authors:  F Broly; U A Meyer
Journal:  Pharmacogenetics       Date:  1993-06

6.  Sparteine oxidation polymorphism: a family study.

Authors:  K Brøsen; S V Otton; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

7.  Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.

Authors:  F J Gonzalez; F Vilbois; J P Hardwick; O W McBride; D W Nebert; H V Gelboin; U A Meyer
Journal:  Genomics       Date:  1988-02       Impact factor: 5.736

8.  Sparteine oxidation polymorphism in Denmark.

Authors:  K Brøsen; S V Otton; L F Gram
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1985-11

9.  Sparteine metabolism in Canadian Caucasians.

Authors:  A Vinks; T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

10.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962

View more
  6 in total

1.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

Authors:  L Bathum; E Skjelbo; T K Mutabingwa; H Madsen; M Hørder; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 2.  Therapeutic drug monitoring of psychotropic medications.

Authors:  P B Mitchell
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

3.  An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.

Authors:  D Marez; M Legrand; N Sabbagh; J M Lo-Guidice; P Boone; F Broly
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

4.  Alternative reliable method for cytochrome P450 2D6 poor metabolizers genotyping.

Authors:  E Pindurová; A Zourková; J Zrůstová; J Juřica; A Pavelka
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

5.  Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype.

Authors:  M L Dahl; L Bertilsson; C Nordin
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

6.  Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.

Authors:  H Madsen; K K Nielsen; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.